Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy

By: via Benzinga
Ocera Therapeutics, Inc. (Nasdaq: OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.